Safeguards the innovation pipeline by proactively securing sensitive research data, enhancing risk resilience and ensuring stakeholder confidence in the integrity of AI-driven discoveries.

Explore how AI and large language models are revolutionizing reaction prediction, retrosynthesis planning, and synthetic accessibility scoring.
Learn how to evaluate and optimize AI-generated leads for real-world developability, including solubility, stability, and synthetic tractability.

Explore how knowledge graphs integrate multi-source biological data, such as genetic, proteomic, and clinical information, into unified models that accelerate target discovery and disease understanding, with AI enhancing the extraction of actionable insights.
Learn how data normalization and the latest curation strategies ensure that biological datasets are clean, standardized, and AI-ready, enabling accurate analysis and improved model performance for drug development.

Hear cross-functional perspectives on successfully implementing AI across process development teams, from aligning with quality, IT, and manufacturing to overcoming cultural and technical barriers, with a focus on driving operational efficiency and long-term value.

Harnesses collaborative innovation networks to integrate external expertise and accelerate breakthrough AI development.

Dive deep into how large language models are automating complex planning tasks, from trial feasibility assessments and synthetic protocol generation to cross-functional alignment and regulatory-ready documentation, with real-world examples of scalable implementation and measurable impact.

Explore how AI accelerates the design of complex biologics, including ADCs and engineered cell therapies.
Learn how predictive models improve developability by forecasting linker stability, payload efficacy, and manufacturability.

Explore how AI-driven digital twins and functional models integrate patient-specific biology to identify and validate high-confidence drug targets by simulating system-level responses to genetic or pharmacological perturbations.
Learn how perturbation modelling with multiomic and functional genomics data predicts the effects of interventions on disease pathways, while LLMs synthesize data to uncover and prioritize novel therapeutic targets.

Equip teams with AI tools that capture process knowledge and simulate scale-up scenarios, reducing tech transfer timelines and improving first-batch success rates - critical for aligning R&D, MSAT, and manufacturing expectations early.

Gain actionable strategies for embedding generative AI and large language models into early-phase trial design and execution, from protocol drafting and site selection to patient engagement, accelerating timelines while ensuring data quality and compliance